“My question is… how will “success” be judged in a small trial with a primary outcome of safety and tolerability and 14 secondary exploratory efficacy outcomes?”
In my eyes success will be judged by having enough data to warrant progression to phase III and data good enough to entice big pharma to throw their hat into the ring
Phase 2, page-14
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |